4.5 Article

Endothelial Nicotinic Acetylcholine Receptors and Angiogenesis

期刊

TRENDS IN CARDIOVASCULAR MEDICINE
卷 18, 期 7, 页码 247-253

出版社

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2008.11.007

关键词

-

资金

  1. NATIONAL CANCER INSTITUTE [R01CA098303] Funding Source: NIH RePORTER
  2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL087746, R21HL085743, R01HL075774] Funding Source: NIH RePORTER
  3. NCI NIH HHS [R01CA098303] Funding Source: Medline
  4. NHLBI NIH HHS [K12 HL087746, 1K12HL087746, R01 HL075774-01, R01 HL-75774, R21 HL085743, R21 HL085743-01, R01 HL075774, K12 HL087746-01] Funding Source: Medline

向作者/读者索取更多资源

Nicotinic acetylcholine receptors (nAChRs) were first described in non-excitable cells just more than a decade ago. The nAChRs on endothelial cells modulate key angiogenic processes, including endothelial cell survival, proliferation, and migration. The receptors may be stimulated by endogenous agonists such as acetylcholine, or exogenous chemicals such as nicotine, to activate physiologic angiogenesis (such as in wound healing) or pathologic angiogenesis (Such as retinal neovascularization or tumor angiogenesis). The endothelial nAChRs may represent a target for therapeutic modulation of disorders characterized by insufficient or pathologic angiogenesis (Trends Cardicivasc Med 2008;18:247-253) (C) 2008, Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据